The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex Times
Back to front
Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL as it pushes forward in eye-care devices
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 26, 10:26 AM EDT

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL as it pushes forward in eye-care devices

The company said on June 11 that the TECNIS PureSee intraocular lens (IOL), an extended depth of focus technology used in cataract procedures, became available across the United States.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Johnson & Johnson’s medical technology business took another step forward in eye-care devices with an update aimed at broadening access to its TECNIS PureSee intraocular lens, or IOL, for use in cataract surgery. According to a market report posted June 26, the company expanded the lens’s availability in the United States on June 11.

The TECNIS PureSee IOL is positioned as an “advanced extended depth of focus” lens. In plain terms, it is an artificial lens implanted in the eye to replace the eye’s natural lens after cataract removal. Extended depth of focus technology is designed to help patients see across multiple distances, with the goal of reducing the need for reading glasses for many everyday tasks.

The market report frames the June 11 expansion as a move to increase where the product can be used in the U.S. healthcare system. While the report does not lay out geographic details or participating centers, it characterizes the update as an availability expansion rather than a new clinical milestone or regulatory clearance event.

IOL competition is intense because these implants sit at the center of cataract surgery outcomes and patient satisfaction. Beyond classic monofocal lenses, lens makers have been offering designs intended to improve functional vision. Extended depth of focus products are part of that broader push, as clinicians and manufacturers try to balance distance performance, intermediate vision, and near vision without unduly increasing unwanted optical effects.

For Johnson & Johnson, which operates through a healthcare portfolio spanning pharmaceuticals, medical devices, and surgical solutions, scaling access to a specific eye-care implant can matter operationally. Expanding availability can support sales through broader surgeon and clinic adoption, and it can also strengthen a product platform if devices are consistently used within a network of providers.

The disclosure in the market report is narrowly focused. It does not specify whether the expansion covered additional indications beyond the existing intended use, does not name new payer coverage rules, and does not provide financial or unit-sales figures. It also does not state whether the company has made changes to manufacturing capacity, distribution terms, or pricing as part of the June 11 rollout.

Why It Matters

  • Broadening availability of an IOL can increase access for surgeons and patients choosing cataract surgery options that target improved visual range.
  • Extended depth of focus lenses represent a key category in modern cataract-device competition, where adoption can depend on where and how quickly products can be used.
  • Because the disclosure does not include pricing, reimbursement, or sales figures, investors and clinicians will likely watch for additional updates on uptake and outcomes rather than immediate financial impact.

Sources

Key Facts

  • Johnson & Johnson expanded U.S. availability of the TECNIS PureSee intraocular lens on June 11.
  • The lens is described as an advanced extended depth of focus IOL.
  • Extended depth of focus refers to lens designs intended to support vision across multiple distances after cataract surgery.
  • The June 26 market report attributes the availability expansion to the company and ties it to the eye-care device product.

Healthcare Related

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL as it pushes forward in eye-care devices | The Apex Times